I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab…
I-Mab a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced positive interim data from its U.S. phase…
Read More...
Read More...
